Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 4, Issue 3, 2014, Pages 152-163

  Okombo, John ^a   Kamau, Alice W ^a   Marsh, Kevin ^a   Sutherland, Colin J ^b   Ochola Oyier, Lynette Isabella ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antimalarial policy; Drug resistance; Microsatellites; Pfcrt; Pfdhfr; Pfmdr1

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; DIHYDROFOLATE REDUCTASE; MULTIDRUG RESISTANCE PROTEIN; PYRIMETHAMINE PLUS SULFADOXINE; PYRIMETHAMINE; SULFADOXINE;

ALLELE; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BLOOD SAMPLING; DRUG TOLERANCE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC HETEROGENEITY; GENOTYPE; HAPLOTYPE; HEALTH CARE POLICY; HUMAN; MALARIA FALCIPARUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE PREVALENCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SELECTIVE SWEEP; CODON; CONTROLLED STUDY; DRUG WITHDRAWAL; GENE; GENE MUTATION; IC50; KENYA; PFCRT GENE; PFDHFR GENE; PFMDR1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84908209146     PISSN: 22113207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2014.07.003     Document Type: Article

References (61)

1. Alam M.T., de Souza D.K., Vinayak S., Griffing S.M., Poe A.C., Duah N.O., Ghansah A., Asamoa K., Slutsker L., Wilson M.D., Barnwell J.W., Udhayakumar V., Koram K.A. Selective sweeps and genetic lineages of Plasmodium falciparum drug-resistant alleles in Ghana. J. Infect. Dis. 2011, 203:220-227.
2. Amin A.A., Zurovac D., Kangwana B.B., Greenfield J., Otieno D.N., Akhwale W.S., Snow R.W. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar. J. 2007, 6:72.
3. Anderson T.J., Su X.Z., Bockarie M., Lagog M., Day K.P. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 1999, 119(Pt 2):113-125.
4. Ariey F., Witkowski B., Amaratunga C., Beghain J., Langlois A.C., Khim N., Kim S., Duru V., Bouchier C., Ma L., Lim P., Leang R., Duong S., Sreng S., Suon S., Chuor C.M., Bout D.M., Menard S., Rogers W.O., Genton B., Fandeur T., Miotto O., Ringwald P., Le Bras J., Berry A., Barale J.C., Fairhurst R.M., Benoit-Vical F., Mercereau-Puijalon O., Menard D. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014, 505:50-55.
5. Chan C.W., Spathis R., Reiff D.M., McGrath S.E., Garruto R.M., Lum J.K. Diversity of Plasmodium falciparum chloroquine resistance transporter (pfcrt) exon 2 haplotypes in the Pacific from 1959 to 1979. PLoS ONE 2012, 7:e30213.
6. Conrad M.D., LeClair N., Arinaitwe E., Wanzira H., Kakuru A., Bigira V., Muhindo M., Kamya M.R., Tappero J.W., Greenhouse B., Dorsey G., Rosenthal P.J. Comparative impacts over 5years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J. Infect. Dis. 2014, 210:344-353.
7. Dahlstrom S., Aubouy A., Maiga-Ascofare O., Faucher J.F., Wakpo A., Ezinmegnon S., Massougbodji A., Houze P., Kendjo E., Deloron P., Le Bras J., Houze S. Plasmodium falciparum polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin. Antimicrob. Agents Chemother. 2014, 58:1-10.
8. Dokomajilar C., Nsobya S.L., Greenhouse B., Rosenthal P.J., Dorsey G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob. Agents Chemother. 2006, 50:1893-1895.
9. Eriksen J., Nsimba S.E., Minzi O.M., Sanga A.J., Petzold M., Gustafsson L.L., Warsame M.Y., Tomson G. Adoption of the new antimalarial drug policy in Tanzania - a cross-sectional study in the community. Trop. Med. Int. Health 2005, 10:1038-1046.
10. Eyase F.L., Akala H.M., Ingasia L., Cheruiyot A., Omondi A., Okudo C., Juma D., Yeda R., Andagalu B., Wanja E., Kamau E., Schnabel D., Bulimo W., Waters N.C., Walsh D.S., Johnson J.D. The role of pfmdr1 and pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011. PLoS ONE 2013, 8:e64299.
11. Fidock D.A., Nomura T., Talley A.K., Cooper R.A., Dzekunov S.M., Ferdig M.T., Ursos L.M., Sidhu A.B., Naude B., Deitsch K.W., Su X.Z., Wootton J.C., Roepe P.D., Wellems T.E. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 2000, 6:861-871.
12. Froberg G., Jornhagen L., Morris U., Shakely D., Msellem M.I., Gil J.P., Bjorkman A., Martensson A. Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar. Malar. J. 2012, 11:321.
13. Frosch A.E., Laufer M.K., Mathanga D.P., Takala-Harrison S., Skarbinski J., Claassen C.W., Dzinjalamala F.K., Plowe C.V. Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J. Infect. Dis. 2014, 10.1093/infdis/jiu216.
14. Gadalla N.B., Adam I., Elzaki S.E., Bashir S., Mukhtar I., Oguike M., Gadalla A., Mansour F., Warhurst D., El-Sayed B.B., Sutherland C.J. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob. Agents Chemother. 2011, 55:5408-5411.
15. Hallett R.L., Dunyo S., Ord R., Jawara M., Pinder M., Randall A., Alloueche A., Walraven G., Targett G.A., Alexander N., Sutherland C.J. Chloroquine/sulphadoxine-pyrimethamine for Gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin. Trials 2006, 1:e15.
16. Hamel M.J., Poe A., Bloland P., McCollum A., Zhou Z., Shi Y.P., Ouma P., Otieno K., Vulule J., Escalante A., Udhayakumar V., Slutsker L. Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:338-345.
17. Henriques G., Hallett R.L., Beshir K.B., Gadalla N.B., Johnson R.E., Burrow R., van Schalkwyk D.A., Sawa P., Omar S.A., Clark T.G., Bousema T., Sutherland C.J. Directional selection at the pfmdr1, pfcrt, pfubp1 and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J. Infect. Dis. 2014, 10.1093/infdis/jiu358.
18. Humphreys G.S., Merinopoulos I., Ahmed J., Whitty C.J., Mutabingwa T.K., Sutherland C.J., Hallett R.L. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob. Agents Chemother. 2007, 51:991-997.
19. Kamya M.R., Bakyaita N.N., Talisuna A.O., Were W.M., Staedke S.G. Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. Trop. Med. Int. Health 2002, 7:1031-1041.
20. Kiara S.M., Okombo J., Masseno V., Mwai L., Ochola I., Borrmann S., Nzila A. In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation. Antimicrob. Agents Chemother. 2009, 53:3793-3798.
21. Koenderink J.B., Kavishe R.A., Rijpma S.R., Russel F.G. The ABCs of multidrug resistance in malaria. Trends Parasitol. 2010, 26:440-446.
22. Kublin J.G., Cortese J.F., Njunju E.M., Mukadam R.A., Wirima J.J., Kazembe P.N., Djimde A.A., Kouriba B., Taylor T.E., Plowe C.V. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 2003, 187:1870-1875.
23. Laufer M.K., Takala-Harrison S., Dzinjalamala F.K., Stine O.C., Taylor T.E., Plowe C.V. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J. Infect. Dis. 2010, 202:801-808.
24. Lekana-Douki J.B., Dinzouna Boutamba S.D., Zatra R., Zang Edou S.E., Ekomy H., Bisvigou U., Toure-Ndouo F.S. Increased prevalence of the Plasmodium falciparum pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine. Infect. Genet. Evol. 2011, 11:512-517.
25. Levy S.B. Balancing the drug-resistance equation. Trends Microbiol. 1994, 2:341-342.
26. Ly O., Gueye P.E., Deme A.B., Dieng T., Badiane A.S., Ahouidi A.D., Diallo M., Bei A.K., Wirth D.F., Mboup S., Sarr O. Evolution of the pfcrt T76 and pfmdr1 Y86 markers and chloroquine susceptibility 8years after cessation of chloroquine use in Pikine, Senegal. Parasitol. Res. 2012, 111:1541-1546.
27. Malmberg M., Ferreira P.E., Tarning J., Ursing J., Ngasala B., Bjorkman A., Martensson A., Gil J.P. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J. Infect. Dis. 2013, 207:842-847.
28. Malmberg M., Ngasala B., Ferreira P.E., Larsson E., Jovel I., Hjalmarsson A., Petzold M., Premji Z., Gil J.P., Bjorkman A., Martensson A. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar. J. 2013, 12:103.
29. Mang'era C.M., Mbai F.N., Omedo I.A., Mireji P.O., Omar S.A. Changes in genotypes of Plasmodium falciparum human malaria parasite following withdrawal of chloroquine in Tiwi, Kenya. Acta Trop. 2012, 123:202-207.
30. Martensson A., Stromberg J., Sisowath C., Msellem M.I., Gil J.P., Montgomery S.M., Olliaro P., Ali A.S., Bjorkman A. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin. Infect. Dis. 2005, 41:1079-1086.
31. Mbogo G.W., Nankoberanyi S., Tukwasibwe S., Baliraine F.N., Nsobya S.L., Conrad M.D., Arinaitwe E., Kamya M., Tappero J., Staedke S.G., Dorsey G., Greenhouse B., Rosenthal P.J. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am. J. Trop. Med. Hyg. 2014, 91:54-61.
32. McCollum A.M., Poe A.C., Hamel M., Huber C., Zhou Z., Shi Y.P., Ouma P., Vulule J., Bloland P., Slutsker L., Barnwell J.W., Udhayakumar V., Escalante A.A. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J. Infect. Dis. 2006, 194:189-197.
33. Moussiliou A., Sissinto-Savi De Tove Y., Doritchamou J., Luty A.J., Massougbodji A., Alifrangis M., Deloron P., Tuikue Ndam N. High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Malar. J. 2013, 12:195.
34. Mutabingwa T.K., Muze K., Ord R., Briceno M., Greenwood B.M., Drakeley C., Whitty C.J. Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. PLoS ONE 2009, 4:e5138.
35. Mwai L., Kiara S.M., Abdirahman A., Pole L., Rippert A., Diriye A., Bull P., Marsh K., Borrmann S., Nzila A. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob. Agents Chemother. 2009, 53:5069-5073.
36. Mwai L., Ochong E., Abdirahman A., Kiara S.M., Ward S., Kokwaro G., Sasi P., Marsh K., Borrmann S., Mackinnon M., Nzila A. Chloroquine resistance before and after its withdrawal in Kenya. Malar. J. 2009, 8:106.
37. Nair S., Williams J.T., Brockman A., Paiphun L., Mayxay M., Newton P.N., Guthmann J.P., Smithuis F.M., Hien T.T., White N.J., Nosten F., Anderson T.J. A selective sweep driven by pyrimethamine treatment in southeast Asian malaria parasites. Mol. Biol. Evol. 2003, 20:1526-1536.
38. Nair S., Miller B., Barends M., Jaidee A., Patel J., Mayxay M., Newton P., Nosten F., Ferdig M.T., Anderson T.J. Adaptive copy number evolution in malaria parasites. PLoS Genet. 2008, 4:e1000243.
39. Ndiaye M., Faye B., Tine R., Ndiaye J.L., Lo A., Abiola A., Dieng Y., Ndiaye D., Hallett R., Alifrangis M., Gaye O. Assessment of the molecular marker of Plasmodium falciparum chloroquine resistance (Pfcrt) in Senegal after several years of chloroquine withdrawal. Am. J. Trop. Med. Hyg. 2012, 87:640-645.
40. Nwakanma D.C., Duffy C.W., Amambua-Ngwa A., Oriero E.C., Bojang K.A., Pinder M., Drakeley C.J., Sutherland C.J., Milligan P.J., Macinnis B., Kwiatkowski D.P., Clark T.G., Greenwood B.M., Conway D.J. Changes in malaria parasite drug resistance in an endemic population over a 25-year period with resulting genomic evidence of selection. J. Infect. Dis. 2014, 209:1126-1135.
41. Nzila A.M., Nduati E., Mberu E.K., Hopkins Sibley C., Monks S.A., Winstanley P.A., Watkins W.M. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J. Infect. Dis. 2000, 181:2023-2028.
42. Omar S.A., Adagu I.S., Gump D.W., Ndaru N.P., Warhurst D.C. Plasmodium falciparum in Kenya: high prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic area. Ann. Trop. Med. Parasitol. 2001, 95:661-669.
43. Ord R., Alexander N., Dunyo S., Hallett R., Jawara M., Targett G., Drakeley C.J., Sutherland C.J. Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J. Infect. Dis. 2007, 196:1613-1619.
44. Peterson D.S., Walliker D., Wellems T.E. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:9114-9118.
45. Price R.N., Uhlemann A.C., van Vugt M., Brockman A., Hutagalung R., Nair S., Nash D., Singhasivanon P., Anderson T.J., Krishna S., White N.J., Nosten F. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 2006, 42:1570-1577.
46. Raman J., Mauff K., Muianga P., Mussa A., Maharaj R., Barnes K.I. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS ONE 2011, 6:e25992.
47. Roper C., Pearce R., Nair S., Sharp B., Nosten F., Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004, 305:1124.
48. Sa J.M., Twu O., Hayton K., Reyes S., Fay M.P., Ringwald P., Wellems T.E. Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18883-18889.
49. Shretta R., Omumbo J., Rapuoda B., Snow R.W. Using evidence to change antimalarial drug policy in Kenya. Trop. Med. Int. Health 2000, 5:755-764.
50. Sisowath C., Stromberg J., Martensson A., Msellem M., Obondo C., Bjorkman A., Gil J.P. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J. Infect. Dis. 2005, 191:1014-1017.
51. Sisowath C., Petersen I., Veiga M.I., Martensson A., Premji Z., Bjorkman A., Fidock D.A., Gil J.P. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Infect. Dis. 2009, 199:750-757.
52. Temu E.A., Kimani I., Tuno N., Kawada H., Minjas J.N., Takagi M. Monitoring chloroquine resistance using Plasmodium falciparum parasites isolated from wild mosquitoes in Tanzania. Am. J. Trop. Med. Hyg. 2006, 75:1182-1187.
53. Thomsen T.T., Madsen L.B., Hansson H.H., Tomas E.V., Charlwood D., Bygbjerg I.C., Alifrangis M. Rapid selection of Plasmodium falciparum chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique. Am. J. Trop. Med. Hyg. 2013, 88:536-541.
54. Triglia T., Menting J.G., Wilson C., Cowman A.F. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13944-13949.
55. van Dillen J., Custers M., Wensink A., Wouters B., van Voorthuizen T., Voorn W., Khan B., Muller L., Nevill C. A comparison of amodiaquine and sulfadoxine-pyrimethamine as first-line treatment of falciparum malaria in Kenya. Trans. R. Soc. Trop. Med. Hyg. 1999, 93:185-188.
56. van Eijk A.M., Hill J., Larsen D.A., Webster J., Steketee R.W., Eisele T.P., ter Kuile F.O. Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11. Lancet Infect. Dis. 2013, 13:1029-1042.
57. Vinayak S., Alam M.T., Sem R., Shah N.K., Susanti A.I., Lim P., Muth S., Maguire J.D., Rogers W.O., Fandeur T., Barnwell J.W., Escalante A.A., Wongsrichanalai C., Ariey F., Meshnick S.R., Udhayakumar V. Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia. J. Infect. Dis. 2010, 201:1551-1560.
58. Wang P., Lee C.S., Bayoumi R., Djimde A., Doumbo O., Swedberg G., Dao L.D., Mshinda H., Tanner M., Watkins W.M., Sims P.F., Hyde J.E. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol. Biochem. Parasitol. 1997, 89:161-177.
59. White N. Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: sulfadoxine-pyrimethamine is not working in Malawi. BMJ 2004, 328:1259. author reply 1260.
60. Wootton J.C., Feng X., Ferdig M.T., Cooper R.A., Mu J., Baruch D.I., Magill A.J., Su X.Z. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002, 418:320-323.
61. World Health Organization, W., 2012. Evidence Review Group: Intermittent Preventive Treatment of Malaria in pregnancy (IPTp) with Sulfadoxine-Pyrimethamine (SP). Geneva: WHO. http://www.who.int/malaria/mpac/sep2012/iptp_sp_erg_meeting_report_july2012.pdf.